Watch ARWR. Know when insiders buy.
One email the day a filing lands. Free.
Work order
44
WATCH · insiders 25, shorts 62
Insiders, 90 days
−$1.2M
net selling · 0 buys, 2 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $12.2BP/E —DIV YIELD —FCF YIELD -0.62%REV TTM $669.5M +16.8%NET INCOME −$320MNET CASH —52W 27.17 – 89.59SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q3 2026 · Jun 30 | $75.3M | +171.0% | — | −$170.1M | −$194.3M | — | -1.36 | −$177.5M | $3.9M | −$181.3M | Aug 4 |
| Q2 2026 · Mar 31 | $73.7M | −86.4% | — | −$141.3M | −$132.7M | −135.8% | -0.93 | $84.4M | $2.6M | $81.9M | May 7 |
| Q1 2026 · Dec 31 | $264M | +10461.3% | — | $40.8M | $30.8M | — | 0.22 | $13.5M | $2.1M | $11.3M | Feb 5 |
| Q4 2025 · Sep 30derived | $256.5M | — | — | $44.1M | −$23.8M | — | -0.18 | $20.5M | $7.5M | $13M | Nov 25 |
| Q3 2025 · Jun 30 | $27.8M | — | — | −$165.6M | −$175.2M | — | -1.26 | −$154.7M | $2.4M | −$157.1M | Aug 4 |
| Q2 2025 · Mar 31 | $542.7M | — | — | $381.2M | $370.4M | — | 2.75 | $460.1M | $5.3M | $454.8M | May 7 |
| Q1 2025 · Dec 31 | $2.5M | −29.6% | — | −$161.4M | −$173.1M | — | -1.39 | −$146.3M | $7.5M | −$153.8M | Feb 5 |
| Q4 2024 · Sep 30derived | $0 | −100.0% | — | −$162.2M | −$170.5M | — | -1.37 | −$137.2M | $24.3M | −$161.5M | Nov 25 |
| Q3 2024 · Jun 30 | $0 | — | — | −$176.1M | −$170.8M | — | -1.38 | −$115.4M | $14.4M | −$129.9M | Aug 7 |
| Q2 2024 · Mar 31 | $0 | — | — | −$126.2M | −$125.3M | — | -1.02 | −$92.4M | $34.1M | −$126.5M | May 12 |
| Q1 2024 · Dec 31 | $3.6M | — | — | −$136.5M | −$132.9M | — | -1.24 | −$117.8M | $68.7M | −$186.5M | Feb 10 |
| Q4 2023 · Sep 30derived | $16.1M | — | — | −$108.3M | −$109.7M | — | -1.02 | −$25.9M | $63.9M | −$89.8M | Nov 25 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Sep 30 | $829.4M | — | $98.3M | −$1.6M | -0.2% | -0.01 | $179.6M | $22.7M | $156.9M | — | — |
| FY2024 · to Sep 30 | $3.6M | — | −$601.1M | −$599.5M | -16882.4% | -5.00 | −$462.9M | $141.5M | −$604.3M | — | — |
| FY2023 · to Sep 30 | $240.7M | — | −$205M | −$205.3M | -85.3% | -1.92 | −$153.9M | $176.7M | −$330.6M | — | — |
| FY2022 · to Sep 30 | $243.2M | — | −$178.5M | −$176.1M | -72.4% | -1.67 | −$136.1M | $52.8M | −$188.9M | — | — |
| FY2021 · to Sep 30 | $138.3M | — | −$149M | −$140.8M | -101.9% | -1.36 | $171.3M | $23.6M | $147.7M | — | — |
| FY2020 · to Sep 30 | $88M | — | −$93.2M | −$84.6M | -96.1% | -0.84 | −$95.8M | $12M | −$107.8M | — | — |
Every number comes from ARROWHEAD PHARMACEUTICALS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.